Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.

Abstract excerpt

Mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML), occurring in up to 30% of AML cases. Mutations in IDH lead to abnormal epigenetic regulation in AML cells and block differentiation. Inhibitors of mutated IDH1 and IDH2, vorasidenib, ivosidenib, olutasidenib, and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML. In this...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Enzyme Inhibitors
• IDH1 gene
• IDH2 gene
• Isocitrate Dehydrogenase
• Leukemia, Myeloid, Acute